Novel therapeutic strategies for non‑small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Review)
- Authors:
- Shengyao Ma
- Ruixin Hu
- Xiaobin Xue
- Meihua Qu
- Guoping Sun
-
Affiliations: School of Pharmacy, Qingdao University, Qingdao, Shandong 266071, P.R. China, Department of Pharmacy, Qingdao Seventh People's Hospital, Qingdao, Shandong 266034, P.R. China, Department of Psychiatry, Qingdao Seventh People's Hospital, Qingdao, Shandong 266034, P.R. China, Translational Medical Center, Weifang Second People's Hospital, Weifang, Shandong 261041, P.R. China - Published online on: July 3, 2025 https://doi.org/10.3892/ol.2025.15170
- Article Number: 424
-
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A and Palmieri G: Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 22:6122021. View Article : Google Scholar | |
|
Pirker R: Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol. 32:63–67. 2020. View Article : Google Scholar | |
|
Deng Q, Fang Q, Sun H, Singh AP, Alexander M, Li S, Cheng H and Zhou S: Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Med. 9:2085–2095. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, et al: Lung cancers with concomitant EGFR mutations and ALK rearrangements: Diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 20:1383–1392. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Abbasian MH, Ardekani AM, Sobhani N and Roudi R: The role of genomics and proteomics in lung cancer early detection and treatment. Cancers (Basel). 14:51442022. View Article : Google Scholar : PubMed/NCBI | |
|
Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, et al: EPSILoN: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort. Cancers (Basel). 11:19542019. View Article : Google Scholar : PubMed/NCBI | |
|
Schoenfeld AJ and Hellmann MD: Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 37:443–455. 2020. View Article : Google Scholar | |
|
Vranic S and Gatalica Z: PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol Biomed. 23:15–25. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Liang H, Liu Z, Cai X, Pan Z, Chen D, Li C, Chen Y, He J and Liang W: PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: An indirect comparison. Int J Cancer. 145:3011–3021. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al: Tislelizumab plus chemotherapy vs chemotherapy alone as First-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol. 7:709–717. 2021. View Article : Google Scholar | |
|
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, et al: Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 16:653–664. 2021. View Article : Google Scholar | |
|
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et al: Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:924–937. 2019. View Article : Google Scholar | |
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al: Atezolizumab for First-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA and Herbst RS: Immunotherapy in Non-small cell lung cancer: Facts and hopes. Clin Cancer Res. 25:4592–4602. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jenkins RW, Barbie DA and Flaherty KT: Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118:9–16. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF and Arnold JN: Cytotoxic chemotherapy as an immune stimulus: A molecular perspective on turning up the immunological heat on cancer. Front Immunol. 10:16542019. View Article : Google Scholar | |
|
Galluzzi L, Buqué A, Kepp O, Zitvogel L and Kroemer G: Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 28:690–714. 2015. View Article : Google Scholar | |
|
Park D, Park I, Han B, Baek Y, Moon D, Jeon NL and Doh J: Cytotoxic chemotherapy in a 3D microfluidic device induces dendritic cell recruitment and trogocytosis of cancer cells. Cancer Immunol Res. 13:931–938. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Heraudet L, Delon T, Veillon R, Vergnenègre C, Lepetit H, Daste A, Ravaud A, Zysman M and Domblides C: Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study. Thoracic Cancer. 13:1391–1400. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, et al: Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 4:1543–1552. 2018. View Article : Google Scholar | |
|
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al: Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with First-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6:1571–1580. 2020. View Article : Google Scholar | |
|
Zouein J, Haddad FG, Eid R and Kourie HR: The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: The rational choice. Immunotherapy. 14:155–167. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, et al: Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 41:1992–1998. 2023. View Article : Google Scholar | |
|
Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 38:1505–1517. 2020. View Article : Google Scholar | |
|
Wang M, Li J, Xu S, Li Y, Li J, Yu J, Tang X and Zhu H: Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients. Cancer Med. 12:5352–5363. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai JS, Wei SH, Chen CW, Yang SC, Tseng YL, Su PL, Lin CC and Su WC: Pembrolizumab and chemotherapy combination prolonged progression-free survival in patients with NSCLC with high PD-L1 expression and low Neutrophil-to-Lymphocyte ratio. Pharmaceuticals (Basel). 15:14072022. View Article : Google Scholar : PubMed/NCBI | |
|
Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, et al: IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in First-line metastatic nonsquamous NSCLC. J Thorac Oncol. 16:1909–1924. 2021. View Article : Google Scholar | |
|
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, et al: Pembrolizumab plus chemotherapy in squamous Non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 41:1999–2006. 2023. View Article : Google Scholar | |
|
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J, et al: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 15:1657–1669. 2020. View Article : Google Scholar | |
|
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, et al: Atezolizumab in combination with carboplatin and Nab-Paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. J Thorac Oncol. 15:1351–1360. 2020. View Article : Google Scholar | |
|
Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al: Tislelizumab plus chemotherapy as First-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial. J Thorac Oncol. 16:1512–1522. 2021. View Article : Google Scholar | |
|
Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, et al: Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol. 42:4029–4039. 2024. View Article : Google Scholar | |
|
Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, Provencio M, Robinson A, Fülöp A, et al: Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782. Lung Cancer. 190:1075062024. View Article : Google Scholar : PubMed/NCBI | |
|
Khan KA and Kerbel RS: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 15:310–324. 2018. View Article : Google Scholar | |
|
Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 18:602019. View Article : Google Scholar : PubMed/NCBI | |
|
Qin H, Yu H, Sheng J, Zhang D, Shen N, Liu L, Tang Z and Chen X: PI3Kgamma inhibitor attenuates immunosuppressive effect of Poly(l-Glutamic Acid)-combretastatin A4 conjugate in metastatic breast cancer. Adv Sci (Weinh). 6:19003272019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu L, Xu J, Qiao R, Zhong H, Brueckl WM and Zhong R: Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: A retrospective comparative cohort study. Transl Lung Cancer Res. 12:1108–1121. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F and Coukos G: Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 20:607–615. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ghisoni E, Imbimbo M, Zimmermann S and Valabrega G: Ovarian cancer immunotherapy: Turning up the Heat. Int J Mol Sci. 20:29272019. View Article : Google Scholar | |
|
Dong Q, Diao Y, Sun X, Zhou Y, Ran J and Zhang J: Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: Protocol for open-label, single-arm trial. BMJ Open. 12:e0499922022. View Article : Google Scholar : PubMed/NCBI | |
|
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, et al: Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 34:2969–2979. 2016. View Article : Google Scholar | |
|
Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, et al: Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced Treatment-naive NSCLC. J Thorac Oncol. 16:289–298. 2021. View Article : Google Scholar | |
|
Huang D, Cui P, Huang Z, Wu Z, Tao H, Zhang S, Xiang R and Hu Y: Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 147:881–891. 2021. View Article : Google Scholar | |
|
Yuan S, Peng L, Liu Y, Till BG, Yan X, Zhang J, Zhu L, Wang H, Zhang S, Li H, et al: Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. Cancer Immunol Immunother. 72:437–448. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin A, Wei T, Meng H, Luo P and Zhang J: Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 18:1392019. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, et al: Low PD-1 expression in cytotoxic CD8+ Tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 24:407–419. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN and Rimm DL: Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. J Thorac Oncol. 13:1884–1896. 2018. View Article : Google Scholar | |
|
Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, et al: Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 5:eaav39372020. View Article : Google Scholar | |
|
Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, et al: BRAF inhibitors: Molecular targeting and immunomodulatory actions. Cancers (Basel). 12:18232020. View Article : Google Scholar : PubMed/NCBI | |
|
Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, de Castro G Jr, Turna HZ, Cristescu R, Aurora-Garg D, et al: Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: Pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 34:377–388. 2023. View Article : Google Scholar | |
|
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, et al: CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8:216–233. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM and Weber J: HDAC Inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 3:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rudin CM, Cervantes A, Dowlati A, Besse B, Ma B, Costa DB, Schmid P, Heist R, Villaflor VM, Spahn J, et al: Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open. 8:1011602023. View Article : Google Scholar : PubMed/NCBI | |
|
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al: TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 31:507–516. 2020. View Article : Google Scholar | |
|
Shi Y, Ji M, Jiang Y, Yin R, Wang Z, Li H, Wang S, He K, Ma Y, Wang Z, et al: A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world. Transl Lung Cancer Res. 11:1051–1068. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
He L, Chen X, Ding L and Zhang X: Clinical efficacy of antianlotinib combined with immune checkpoint inhibitors in the treatment of advanced Non-small-cell lung cancer and its effect on serum VEGF, CEA, and SCC-Ag. J Oncol. 2022:15308752022. View Article : Google Scholar | |
|
Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H and Patnaik A: Pembrolizumab in combination with erlotinib or gefitinib as First-line therapy for advanced NSCLC with sensitizing EGFR mutation. J Thorac Oncol. 14:553–559. 2019. View Article : Google Scholar | |
|
Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, et al: JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer. 128:65–74. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, et al: Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166:107–113. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Qin L, Wang X, Wang W, Li J, Wang H, Li H, Cai X, Yang Y and Qu M: The expression of VISTA on CD4+ T cells associate with poor prognosis and immune status in non-small cell lung cancer patients. Bosn J Basic Med Sci. 22:707–715. 2022. View Article : Google Scholar | |
|
O'Donnell JS, Teng MWL and Smyth MJ: Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 16:151–167. 2019. View Article : Google Scholar | |
|
Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J and Giles F: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 6:392018. View Article : Google Scholar : PubMed/NCBI | |
|
Eggermont AMM, Crittenden M and Wargo J: Combination immunotherapy development in melanoma. Am Soc Clin Oncol Educ Book. 38:197–207. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, et al: A First-in-human study and biomarker analysis of NKTR-214, a Novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 9:711–721. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hollingsworth RE and Jansen K: Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 4:72019. View Article : Google Scholar : PubMed/NCBI | |
|
Feins S, Kong W, Williams EF, Milone MC and Fraietta JA: An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 94 (Suppl):S3–S9. 2019. View Article : Google Scholar | |
|
Chen X, Wang Q, Cong X, Jiang S, Li S, Shen Q and Chen L: sCD40L is increased and associated with the risk of gestational diabetes mellitus in pregnant women with isolated TPOAb positivity. Int J Endocrinol. 2022:29468912022. View Article : Google Scholar | |
|
Cerezo M and Rocchi S: Cancer cell metabolic reprogramming: A keystone for the response to immunotherapy. Cell Death Dis. 11:9642020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Q, Jiang H, Ma L, Zhao G, Xu Q, Guo D, He N, Liu H, Meng Z, Liu J, et al: The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation. Proc Natl Acad Sci USA. 120:e22094351202023. View Article : Google Scholar : PubMed/NCBI | |
|
Guerra L, Bonetti L and Brenner D: Metabolic modulation of immunity: A new concept in cancer immunotherapy. Cell Rep. 32:1078482020. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X: Structure and functions of T-cell immunoglobulin-domain and Mucin-domain Protein 3 in cancer. Curr Med Chem. 29:1851–1865. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, Jalili A and Jadidi-Niaragh F: T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life. 73:726–738. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lee WJ, Lee YJ, Choi ME, Yun KA, Won CH, Lee MW, Choi JH and Chang SE: Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes. J Am Acad Dermatol. 81:219–227. 2019. View Article : Google Scholar | |
|
Peng Y, Qiu B, Tan F, Xu J, Bie F, He H, Liu L, Tian H, Bai G, Zhou B, et al: TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. Thoracic Cancer. 13:2014–2023. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ait Boujmia OK: V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: A Bibliometric study. Naunyn Schmiedebergs Arch Pharmacol. 394:1057–1065. 2021. View Article : Google Scholar | |
|
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, et al: First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, Open-Label, phase 3 CheckMate 227 Part 1 trial. J Thorac Oncol. 17:289–308. 2022. View Article : Google Scholar | |
|
Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, et al: Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: A phase 1a/1b nonrandomized controlled trial. JAMA Oncol. 9:1574–1582. 2023. View Article : Google Scholar | |
|
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, et al: Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23:781–792. 2022. View Article : Google Scholar | |
|
Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, et al: ARCTIC: Durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 31:609–618. 2020. View Article : Google Scholar | |
|
Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, et al: Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%: Randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 39:2327–2338. 2021. View Article : Google Scholar | |
|
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al: Durvalumab with or without tremelimumab vs standard chemotherapy in First-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 6:661–674. 2020. View Article : Google Scholar | |
|
Stockwell J, Jakova E and Cayabyab FS: Adenosine A1 and A2A receptors in the Brain: Current research and their role in neurodegeneration. Molecules. 22:6762017. View Article : Google Scholar : PubMed/NCBI | |
|
Allard B, Longhi MS, Robson SC and Stagg J: The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 276:121–144. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Campos-Contreras ADR, González-Gallardo A, Díaz-Muñoz M and Vázquez-Cuevas FG: Adenosine receptor A2B negatively regulates cell migration in ovarian carcinoma cells. Int J Mol Sci. 23:45852022. View Article : Google Scholar | |
|
Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD and Colombo MP: Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood. 105:2845–2851. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Diab A, Hamid O, Thompson JA, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, et al: A Phase I, Open-Label, Dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers. Clin Cancer Res. 28:71–83. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Canel M, Taggart D, Sims AH, Lonergan DW, Waizenegger IC and Serrels A: T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. Elife. 9:e480922020. View Article : Google Scholar : PubMed/NCBI | |
|
Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J and Weinberg AD: Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 33:798–809. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Waldmann TA: Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 10:6–15. 2018. View Article : Google Scholar | |
|
Benjamin DJ and Lyou Y: Advances in immunotherapy and the TGF-β resistance pathway in metastatic bladder cancer. Cancers (Basel). 13:57242021. View Article : Google Scholar : PubMed/NCBI | |
|
Derynck R, Muthusamy BP and Saeteurn KY: Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 31:56–66. 2014. View Article : Google Scholar | |
|
Wu S, Wang Y, Yuan Z, Wang S, Du H, Liu X, Wang Q and Zhu X: Human adipose-derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial-mesenchymal transition by cross interacting with the TGF-β/Smad and PI3K/AKT signaling pathways. Mol Med Rep. 19:177–186. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, et al: Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget. 9:6659–6677. 2018. View Article : Google Scholar | |
|
Jung SY, Hwang S, Clarke JM, Bauer TM, Keedy VL, Lee H, Park N, Kim SJ and Lee JI: Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Invest New Drugs. 38:812–820. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, et al: Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: Phase I Dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 10:1158–1173. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DW and Cho JY: Recent advances in allogeneic CAR-T cells. Biomolecules. 10:2632020. View Article : Google Scholar : PubMed/NCBI | |
|
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al: A Phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, Non-small cell lung cancer, or bladder cancer. Cell. 183:347–362.e24. 2020. View Article : Google Scholar | |
|
Raja J, Ludwig JM, Gettinger SN, Schalper KA and Kim HS: Oncolytic virus immunotherapy: Future prospects for oncology. J Immunother Cancer. 6:1402018. View Article : Google Scholar : PubMed/NCBI | |
|
Lawler SE, Speranza MC, Cho CF and Chiocca EA: Oncolytic viruses in cancer treatment: A review. JAMA Oncol. 3:841–849. 2017. View Article : Google Scholar | |
|
Zheng Y, Wang PP, Fu Y, Chen YY and Ding ZY: Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. Int Immunopharmacol. 110:1090302022. View Article : Google Scholar | |
|
Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauquil C, Ederhy S, et al: The 2016–2019 immunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. Eur J Cancer. 130:39–50. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S and Péron J: A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 145:639–648. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, et al: Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 79:332–338. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Patrinely JR Jr, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, et al: Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 135:211–220. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al: Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 16:563–580. 2019. View Article : Google Scholar | |
|
Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, et al: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: A PRISMA systematic review and meta-analysis. BMC Cancer. 19:5582019. View Article : Google Scholar : PubMed/NCBI | |
|
Shao J, Wang C, Ren P, Jiang Y, Tian P and Li W: Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 40:BSR201923472020. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi T, Shimizu J, Oya Y, Watanabe N, Hasegawa T, Horio Y, Inaba Y and Fujiwara Y: Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. Thoracic Cancer. 13:724–731. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Long YX, Sun Y, Liu RZ, Zhang MY, Zhao J, Wang YQ, Zhou YW, Cheng K, Chen Y, Zhu CR, et al: Immune-related pneumonitis was decreased by addition of chemotherapy with PD-1/L1 inhibitors: Systematic review and network meta-analysis of randomized controlled trials (RCTs). Curr Oncol. 29:267–282. 2022. View Article : Google Scholar | |
|
Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, et al: Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): A multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 20:1109–1123. 2019. View Article : Google Scholar | |
|
Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, et al: Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol. 14:933–939. 2019. View Article : Google Scholar | |
|
Hou YL, Wang DY, Hu JX, Tian RY, Wang W, Su Q, Li H and Wang YL: Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and Meta-analysis. Ocul Immunol Inflamm. 30:1449–1459. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G and Torre-Amione G: Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis. Eur J Heart Fail. 23:1739–1747. 2021. View Article : Google Scholar | |
|
Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, et al: Temporal trends and outcomes among patients admitted for Immune-related adverse events: A single-center retrospective cohort study from 2011 to 2018. Oncologist. 26:514–522. 2021. View Article : Google Scholar | |
|
Valencia-Sanchez C and Zekeridou A: Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy. Front Neurol. 12:6428002021. View Article : Google Scholar | |
|
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, et al: Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 82:34–44. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, et al: Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 70:2209–2221. 2021. View Article : Google Scholar : PubMed/NCBI |
